Cargando…

Quantitative Structure-Activity Relationship Studies on Indenoisoquinoline Topoisomerase I Inhibitors as Anticancer Agents in Human Renal Cell Carcinoma Cell Line SN12C

Topoisomerase I is important for DNA replication and cell division, making it an attractive drug target for anticancer therapy. A series of indenoisoquinolines displaying potent Top1 inhibitory activity in human renal cell carcinoma cell line SN12C were selected to establish 3D-QSAR models using CoM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhi, Yi, Yang, Jin, Tian, Shengchao, Yuan, Fang, Liu, Yang, Zhang, Yi, Sun, Pinghua, Song, Bo, Chen, Zhiwen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382809/ https://www.ncbi.nlm.nih.gov/pubmed/22754346 http://dx.doi.org/10.3390/ijms13056009

Ejemplares similares

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins
por: Pommier, Yves, et al.
Publicado: (2018)

Synthesis and Biological Evaluation of New Carbohydrate-Substituted Indenoisoquinoline Topoisomerase I Inhibitors and Improved Syntheses of the Experimental Anticancer Agents Indotecan (LMP400) and Indimitecan (LMP776)
por: Beck, Daniel E., et al.
Publicado: (2014)

Synthesis and Biological Activity of a New Indenoisoquinoline Copper Derivative as a Topoisomerase I Inhibitor
por: Molinaro, Caroline, et al.
Publicado: (2023)

Binding of an Indenoisoquinoline to the Topoisomerase-DNA Complex Induces Reduction of Linker Mobility and Strengthening of Protein-DNA Interaction
por: Mancini, Giordano, et al.
Publicado: (2012)

Design, Synthesis, and Biological Evaluation of O-2-Modified Indenoisoquinolines as Dual Topoisomerase I–Tyrosyl-DNA Phosphodiesterase I Inhibitors
por: Lv, Peng-Cheng, et al.
Publicado: (2014)

A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas
por: Molinaro, Caroline, et al.
Publicado: (2022)

Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome
por: Lee, Hyeong-Min, et al.
Publicado: (2018)

Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
por: Jain, Chetan Kumar, et al.
Publicado: (2017)

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
por: Molinaro, Caroline, et al.
Publicado: (2020)

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
por: Cincinelli, Raffaella, et al.
Publicado: (2018)

Solvent Dependency of the UV-Vis Spectrum of Indenoisoquinolines: Role of Keto-Oxygens as Polarity Interaction Probes
por: Coletta, Andrea, et al.
Publicado: (2013)

Exploring DNA Topoisomerase I Ligand Space in Search of Novel Anticancer Agents
por: Drwal, Malgorzata N., et al.
Publicado: (2011)

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents
por: Okoro, Cosmas O., et al.
Publicado: (2023)

Development of a Folate Receptor (FR)-Targeted Indenoisoquinoline Using a pH-Sensitive N-Ethoxybenzylimidazole (NEBI) Bifunctional Cross-Linker
por: Cao, Yuchen, et al.
Publicado: (2014)

Molecular docking analysis of α-Topoisomerase II with δ-Carboline derivatives as potential anticancer agents
por: Ayyamperumal, Selvaraj, et al.
Publicado: (2021)

DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling
por: Souza, Vinicius, et al.
Publicado: (2005)

On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
por: Wu, Chyuan-Chuan, et al.
Publicado: (2013)

Spheres derived from the human SN12C renal cell carcinoma cell line are enriched in tumor initiating cells
por: Zhang, Yanhui, et al.
Publicado: (2016)

Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II
por: Hawtin, Rachael E., et al.
Publicado: (2010)

Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme
por: Swedan, Hadeer K., et al.
Publicado: (2022)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Bulge oligonucleotide as an inhibitory agent of bacterial topoisomerase I
por: Yang, Zhaoqi, et al.
Publicado: (2017)

A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
por: Li, Zhi-Ying, et al.
Publicado: (2021)

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
por: Xu, Yang, et al.
Publicado: (2015)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations
por: Jensen, Niels Frank, et al.
Publicado: (2016)

Synthesis and Biological Evaluation of Novel 1H-Benzo[d]imidazole Derivatives as Potential Anticancer Agents Targeting Human Topoisomerase I
por: Pandey, Stuti, et al.
Publicado: (2022)

Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells
por: Juchem, André Luiz Mendes, et al.
Publicado: (2023)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.
por: Coutts, J., et al.
Publicado: (1993)

Imidazolylpyrrolone‐Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma
por: Sousa, Ana, et al.
Publicado: (2022)

Expression of the Topoisomerase II Alpha (TOP2A) Gene in Lung Adenocarcinoma Cells and the Association with Patient Outcomes
por: Du, Xiaomei, et al.
Publicado: (2020)

A novel bifunctional mitochondria-targeted anticancer agent with high selectivity for cancer cells
por: He, Huan, et al.
Publicado: (2015)

Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation
por: González-Ruiz, Víctor, et al.
Publicado: (2021)

Investigating the Anticancer Potential of Salvicine as a Modulator of Topoisomerase II and ROS Signaling Cascade
por: Dey, Dipta, et al.
Publicado: (2022)

Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB
por: Ottaviani, Alessio, et al.
Publicado: (2021)

Immunogenic cell death inducers as anticancer agents
por: Kepp, Oliver, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tvc4m4cloc4ev9pl4squvkclhh